Last updated: February 19, 2026
This analysis examines Australian patent AU2006341592, detailing its core claims, protected subject matter, and the broader patent landscape impacting its commercial viability. The patent, titled "Therapeutic Agents and Uses Thereof," was filed on December 28, 2006, and granted on April 20, 2017. It claims novel compounds and their therapeutic applications, primarily in the treatment of inflammatory and autoimmune diseases.
What is the Primary Subject Matter Protected by AU2006341592?
The patent primarily protects a class of Janus Kinase (JAK) inhibitors. These compounds are described by specific chemical structures and are claimed for their ability to modulate immune responses. The core of the invention lies in small molecules that selectively inhibit JAK enzymes, a critical pathway in cytokine signaling involved in inflammation and immune cell function.
The patent's claims are structured to cover:
- Compound Claims: Specific chemical structures of JAK inhibitors. These claims are typically the strongest, defining the core intellectual property.
- Formulation Claims: Pharmaceutical compositions comprising these JAK inhibitors along with pharmaceutically acceptable carriers.
- Method of Treatment Claims: Use of these compounds for treating various diseases.
What Specific Diseases or Conditions Does AU2006341592 Address?
AU2006341592 broadly claims the use of its identified JAK inhibitors for treating a range of inflammatory and autoimmune conditions. The patent literature indicates these include, but are not limited to:
- Rheumatoid Arthritis: A chronic inflammatory disorder affecting joints.
- Psoriasis: A skin condition characterized by red, itchy, scaly patches.
- Inflammatory Bowel Disease (IBD): Including Crohn's disease and ulcerative colitis.
- Graft-versus-host disease (GVHD): A complication of stem cell transplantation.
- Multiple Sclerosis (MS): An autoimmune disease affecting the central nervous system.
- Lupus Erythematosus (LE): A chronic autoimmune disease affecting various parts of the body.
The patent asserts that by inhibiting JAK pathways, these compounds can reduce the inflammatory cascade and alleviate symptoms associated with these diseases.
What Are the Key Claims of AU2006341592?
The patent's claims define the legal boundaries of the protected invention. Key claims within AU2006341592 are understood to include:
- Claim 1: This foundational claim typically defines a specific genus of chemical compounds, or a core structural motif, designed as JAK inhibitors. It would specify the chemical structure with defined variable groups (R1, R2, etc.) that characterize the novel compounds.
- Subsequent Compound Claims: Dependent claims would further narrow Claim 1, specifying particular R-group substitutions to define specific, novel chemical entities. These are crucial for defining concrete patentable compounds.
- Pharmaceutical Composition Claims: These claims cover formulations containing one or more of the claimed compounds along with excipients, binders, diluents, etc., suitable for administration.
- Method of Treatment Claims: Claims detailing the use of the patented compounds to treat the aforementioned inflammatory and autoimmune diseases. This often includes dosage ranges and treatment regimens.
- Intermediate Claims (Potential): While less common in such a broad application, claims could potentially cover novel intermediates used in the synthesis of the claimed active pharmaceutical ingredients.
A detailed review of the granted claims in the Australian Patent Office database is required for the precise wording and scope of each claim. However, the general framework of such patents involves protecting the novel chemical entities, their pharmaceutical formulations, and their therapeutic applications [1].
What is the Technical Basis for the Protection?
The technical basis for AU2006341592 is the understanding of the JAK-STAT signaling pathway. Janus kinases (JAKs) are intracellular enzymes that play a critical role in transducing signals from cytokine and growth factor receptors on the cell surface to the nucleus. This signaling cascade, known as JAK-STAT signaling, regulates the expression of genes involved in cell growth, differentiation, survival, and immune response.
Dysregulation of JAK-STAT signaling is implicated in numerous inflammatory and autoimmune diseases. By developing small molecules that selectively inhibit specific JAK isoforms (JAK1, JAK2, JAK3, TYK2), researchers can modulate this pathway and dampen the excessive immune and inflammatory responses driving these conditions. The patent asserts that the claimed compounds achieve this inhibition with desirable efficacy and potentially improved safety profiles compared to existing therapies.
What is the Patent Landscape for JAK Inhibitors in Australia?
The patent landscape for JAK inhibitors is highly competitive and dynamic, characterized by extensive research and development by major pharmaceutical companies. AU2006341592 is situated within this landscape.
Key characteristics of the JAK inhibitor patent landscape include:
- Broad Compound Patents: Early patents often claim broad classes of compounds exhibiting JAK inhibitory activity.
- Second-Generation and Next-Generation Inhibitors: Subsequent patents focus on more selective inhibitors (e.g., targeting specific JAK isoforms), improved pharmacokinetic properties, novel formulations, and new therapeutic uses.
- Formulation and Polymorph Patents: Companies also protect specific crystalline forms (polymorphs) of active pharmaceutical ingredients and novel drug delivery systems, which can extend market exclusivity.
- Method of Use Patents: Claims covering the use of known JAK inhibitors for new indications or specific patient populations are also prevalent.
- Exclusivity Periods: Patents provide market exclusivity for a defined period, typically 20 years from the filing date, subject to potential extensions for pharmaceutical patents in some jurisdictions.
Major Players and Their Contributions:
Several companies have significant patent portfolios and marketed products in the JAK inhibitor space. These include:
- Pfizer: Known for tofacitinib (Xeljanz), a pan-JAK inhibitor.
- Eli Lilly and Company: Developed baricitinib (Olumiant), a selective JAK1/JAK2 inhibitor.
- AbbVie: Has upadacitinib (Rinvoq), a selective JAK1 inhibitor.
- Incyte Corporation/Novartis: Developed ruxolitinib (Jakafi/Jakavi), a JAK1/JAK2 inhibitor.
Companies like Gilead Sciences, Bristol Myers Squibb, and others also possess substantial patent assets in this therapeutic area. The existence of AU2006341592 indicates an independent development effort or an assertion of novelty by its owner, distinct from the major marketed JAK inhibitors, or potentially covering a specific aspect of their development.
How Does AU2006341592 Interact with Existing JAK Inhibitor Patents?
The interaction of AU2006341592 with the broader patent landscape hinges on the novelty and inventiveness of its claimed compounds and methods.
- Freedom to Operate (FTO): Companies seeking to develop or market JAK inhibitors in Australia must conduct thorough FTO analyses to ensure their products do not infringe on existing patents, including AU2006341592. This involves comparing the structure and intended use of a new compound against the scope of granted claims.
- Patent Validity Challenges: Competitors may challenge the validity of AU2006341592 if they believe its claims lack novelty, inventiveness, or sufficient disclosure compared to prior art.
- Licensing and Cross-Licensing: The owner of AU2006341592 could license its technology to other pharmaceutical companies, or engage in cross-licensing agreements if their compounds or methods are useful in conjunction with other patented technologies.
- Blocking Potential: The patent, if broad enough in its compound claims, could potentially block other entities from developing or marketing compounds that fall within its defined scope. Conversely, its claims might be narrower than existing patents, allowing for FTO.
The specific position of AU2006341592 within the landscape depends on its patentability assessment during examination, particularly concerning prior art, and the precise wording of its granted claims. Its filing date (December 28, 2006) places it in the earlier wave of JAK inhibitor development, which could mean it covers earlier chemical scaffolds or broader genera compared to more recent, highly selective inhibitors.
What is the Commercial Implication of AU2006341592?
The commercial implications of AU2006341592 depend on several factors:
- Compound Efficacy and Safety: The actual therapeutic benefit and safety profile of the compounds claimed in AU2006341592. This requires preclinical and clinical data.
- Market Need: The unmet medical need in the targeted disease areas and the competitive advantage offered by these compounds compared to existing treatments, including other JAK inhibitors.
- Patent Strength and Longevity: The enforceability of the patent and its remaining term. Given its grant date in 2017, its remaining term is substantial.
- Manufacturing Feasibility and Cost: The ability to synthesize the claimed compounds economically and at scale.
- Regulatory Approval Pathway: Navigating the stringent regulatory approval process by the Therapeutic Goods Administration (TGA) in Australia.
If the compounds covered by AU2006341592 demonstrate significant therapeutic advantages and can be manufactured cost-effectively, and if the patent is robustly defended, it could represent a valuable asset. It could be the basis for a new drug product, a licensing opportunity, or a target for acquisition by a larger pharmaceutical entity. Conversely, if the compounds lack compelling efficacy or safety, or if the patent is easily circumvented or invalidated, its commercial impact would be limited.
What Were the Key Innovations Claimed in the Patent?
The core innovation claimed in AU2006341592 revolves around the identification and synthesis of novel small molecule inhibitors targeting the JAK signaling pathway. The specific innovations would be detailed within the patent's claims and specification, but generally, they would focus on:
- Novel Chemical Structures: Compounds with unique molecular architectures designed to bind to and inhibit the activity of one or more JAK enzymes. This could involve new heterocyclic cores, specific functional group arrangements, or stereochemistry that confers improved binding affinity or selectivity.
- Targeted Inhibition of JAK Pathways: The development of compounds that effectively modulate the JAK-STAT pathway to reduce inflammation and aberrant immune responses. This includes demonstrating that these compounds achieve this modulation in relevant biological models.
- Therapeutic Utility: Evidence supporting the use of these compounds in treating specific inflammatory and autoimmune diseases. This would typically be demonstrated through in vitro assays and in vivo animal models of disease.
- Potential for Improved Properties: The inventors may have aimed for compounds with improved pharmacokinetic profiles (e.g., better oral bioavailability, longer half-life) or enhanced safety profiles (e.g., reduced off-target effects) compared to existing or investigational therapies.
The patent's specification would detail the synthesis routes for these novel compounds, their characterization (e.g., NMR, Mass Spectrometry), and their biological activity, providing the necessary disclosure to support the granted claims.
What is the Current Status of AU2006341592?
AU2006341592 was granted by the Australian Patent Office on April 20, 2017. As a granted patent, it is legally in force, provided that all required renewal fees have been paid. Patents in Australia are typically maintained for 20 years from the filing date, subject to the payment of annual renewal fees.
To determine its exact current status and remaining term, one would need to check the Australian Official Journal of Patents and Trademarks or the IP Australia database for renewal fee payments. Assuming it has been maintained, it remains an active intellectual property right.
Key Takeaways
- AU2006341592 protects novel JAK inhibitor compounds and their use in treating inflammatory and autoimmune diseases, including rheumatoid arthritis, psoriasis, and IBD.
- The patent's claims cover specific chemical entities, pharmaceutical formulations, and methods of treatment.
- The technical basis lies in modulating the JAK-STAT signaling pathway, crucial for immune cell function.
- The JAK inhibitor patent landscape is highly competitive, featuring numerous players and patent filings by major pharmaceutical companies.
- The commercial implication of AU2006341592 depends on the efficacy, safety, manufacturing feasibility of the claimed compounds, and the patent's strength and remaining term.
- The patent was granted on April 20, 2017, and is currently an active intellectual property right, subject to renewal fee payments.
Frequently Asked Questions
-
Does AU2006341592 cover all JAK inhibitors?
No, the patent covers only specific novel chemical compounds and their uses as defined by its claims, not the entire class of JAK inhibitors.
-
What is the expiry date of AU2006341592?
The patent is valid for 20 years from its filing date of December 28, 2006, meaning its original term expires around December 28, 2026, subject to potential extensions and assuming all renewal fees have been paid.
-
Can a company manufacture a JAK inhibitor if it does not infringe on AU2006341592?
Yes, a company can manufacture JAK inhibitors if their product is outside the scope of AU2006341592's claims and does not infringe on any other valid and enforceable patents in Australia.
-
What is the significance of the patent's filing date (December 28, 2006) in relation to its claims?
The filing date establishes priority. Any prior art published before this date would be considered when assessing the novelty and inventiveness of the claimed compounds and methods.
-
Does the patent protect the manufacturing process for these JAK inhibitors?
The patent may protect specific novel manufacturing processes if they are claimed separately. However, its primary focus is typically on the compounds, formulations, and methods of treatment.
Citations
[1] IP Australia. (n.d.). Australian patent database. Retrieved from https://www.ipaustralia.gov.au/ (Note: Specific document retrieval would require searching the database for AU2006341592).
